Fintechs

Key Points to Consider Before Entering into a Bank-Fintech Partnership

Key points to consider before entering into a Bank-Fintech partnership

In a world where digital banking is becoming the norm, traditional banks are partnering with Fintech companies to survive. While this can be a great move for both businesses, forging a successful partnership between banks and fintech companies isn’t always easy.

Big banks are not known for their risk-taking ability. However, as the digital revolution makes its way through finance and continues to take market share from banks, taking risks becomes a necessity. As a result, many banks are looking towards fintech startups to partner with in an effort to remain competitive. This move makes financial sense for both parties.

Banks can use their infrastructure and capital to finance fintech startups’ innovation while taking advantage of the startup’s agility. On the other hand, fintech companies have access to banking licenses and a large customer base that they wouldn’t have otherwise had if they were to go it alone.

While this symbiotic relationship is important for any bank and fintech company looking to succeed, it isn’t always easy. From differing business models to vastly different cultures and complex compliance requirements; establishing a successful banking and fintech relationship requires careful planning and consideration.

So let us look at three key factors that banks and fintechs should consider before entering into a partnership.

Regulators

Relationship with regulators is a major point that should be considered by both banks and fintechs before getting into any sort of partnership.

Before partnering with a fintech company, it’s important for banks to consider how well they are regulated. Fintechs must follow federal and state laws, so it’s important to make sure your potential partner is in good standing with the right regulators. If you are a bank then you should also ask the following three questions about how your fintech partner plans to manage regulatory obstacles that are likely to come up in the future.

  • What steps will they take to keep track of and follow the regulations as they change?
  • What legal requirements apply to their present services?
  • Is their software licensed or certified, and what licenses or certifications are they required to have?

Managing compliance can be a daunting task for both banks and fintechs. In order to make sure that the relationship is successful, it’s important for both parties to take the necessary steps to manage compliance. This includes appointing an in-house expert or nominating a senior member of your team to build a relationship with regulatory bodies. It’s also important for banks to develop a vendor management program with oversight over their partners.

Data Security

Data security is a major concern for both banks and fintech companies. In order to ensure a successful partnership, it’s important for both parties to take the necessary steps to protect data.  What sort of security measures do your fintech partners have in place? How does data security tie into existing policies and procedures, and what sort of protection is in place for sensitive customer data? These are all questions that banks should ask prior to any partnership.

However, data security is just one aspect of data protection. It is also important for both banks and fintechs to know how their partners intend to deal with a data breach once it happens.  Is there a plan in place to minimize damage and prevent it from happening again? What would they do if the worst does happen, and how would they inform their customers and partners? These are all questions that need to be answered before entering into any sort of partnership.

The team

Getting to know the team that is running the fintech you are investing in is one of the most important tasks.

The human factor is always overlooked in fintech. We can understand why sometimes, given the amount of money involved and the complexities involved which requires expertise in the field of finance or data science, but it cannot be denied that at least some degree of emotional intelligence would be required. It’s quite easy to look past this fact when real-world use cases are being delivered.

For a bank that is getting into a partnership with a fintech, particularly a young one, it is absolutely vital to analyze the team behind the idea.

First, they should look at the business leadership itself. On this, should be the founders and key people running the daily affairs of the fintech company. They need to do a proper background check and analyze how competent and well-connected these leaders are.

Second, banks need to take a close look at their product development team and ensure that they have the right mix of people with a solid product vision.

In this regard, having a technical co-founder, product managers and software engineers is ideal.

Third, banks need to look at the customer support and marketing teams of the fintech company. Do they have a good understanding of the market challenges? Is their digital presence strong enough? Finally, they should take a close look at how well they have been able to market themselves, how much brand awareness they have been able to generate and what sort of customers they have attracted.

The fact is that a bank partnering with a fintech doesn’t only want the technology or product offering from them, it’s also looking for a strong team with an understanding of its own business needs.

The benefits of partnering with a fintech company are clear, but it’s important to take the time to do your due diligence before entering into any agreement. Make sure you have a clear understanding of the relationship with regulators, data security measures in place, and who will be running the show. With careful planning, both banks and fintech companies can reap the rewards of a fruitful partnership.

Key Points to Consider Before Entering into a Bank-Fintech Partnership

PostAd_coinrule_banner728x90

Comments are closed.

PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

2024-09-19T13:00:00Z

Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

Key contributions from PersonalAIze include:

  • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
  • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
  • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
  • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
  • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:

  • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
  • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
  • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
  • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
  • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
  • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
  • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.


GlobeNewsWire News

Recent Comments